
    
      This is an open-label (all participants and study personnel will know the identity of the
      study treatments) and multicenter (study conducted at multiple sites) study in Japanese
      participants. The study will include a Screening Phase (21 days prior to Cycle 1 Day 1);
      open-label treatment phase (from Cycle 1 Day 1 until study treatment discontinuation, disease
      progression, unacceptable toxicity, or other reasons), and a Follow-up Phase. Bortezomib and
      Dexamethasone will be administered along with JNJ-54767414 for first 8 treatment cycles.
      Follow-up Phase begins immediately following the End-of-Treatment Visit, and will continue
      until 8 weeks after last study treatment, death, loss to follow-up, consent withdrawal for
      study participation, or study end, whichever occurs first. Participants' safety will be
      monitored throughout the study.
    
  